At Acadia, our mission is to turn scientific promise into meaningful innovation that makes the difference for underserved neurological disorders and rare disease communities around the world. Currently, our clinical-stage developments focus on addressing Alzheimer’s disease psychosis and Lewy body dementia psychosis, along with early-stage programs that address other unmet patient needs. We are working to seek approval of our treatment option for people living with Rett syndrome in Europe.
We have submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for our treatment of Rett syndrome.
Our Focus
Our clinical-stage development efforts are focused on Alzheimer’s disease psychosis and multiple other programmes targeting neuropsychiatric symptoms in central nervous system disorders.
